Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population

[1]  Young T. Hong,et al.  The pattern of amyloid accumulation in the brains of adults with Down syndrome , 2016, Alzheimer's & Dementia.

[2]  Sterling C. Johnson,et al.  The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B , 2016, Alzheimer's & Dementia.

[3]  J. Brewer,et al.  The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome , 2015, Front. Behav. Neurosci..

[4]  Peter J Gianaros,et al.  Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study , 2015, The Lancet Neurology.

[5]  Sterling C. Johnson,et al.  Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. , 2014, Brain : a journal of neurology.

[6]  이근호,et al.  ROI(Region Of Interest)기반의 차등적 이미지 압축에 관한 연구 , 2014 .

[7]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[8]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[9]  Lisa A. Weissfeld,et al.  Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches , 2013, NeuroImage.

[10]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[11]  W. Klunk,et al.  Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B , 2012, Alzheimer's & Dementia.

[12]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[13]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[14]  Andrei G. Vlassenko,et al.  Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.

[15]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[16]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[17]  R. Kirby,et al.  Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[18]  S. Faraone,et al.  Review Article: Genetics of Alzheimer Disease , 2010, Journal of geriatric psychiatry and neurology.

[19]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[20]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[21]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[22]  H. Möller,et al.  Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. , 2004, Brain : a journal of neurology.

[23]  Nathan S White,et al.  A voxel-based morphometric study of nondemented adults with Down Syndrome , 2003, NeuroImage.

[24]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[25]  小島 道生,et al.  "Dementia Scale for Down Syndrome" の日本への適用 , 2000 .

[26]  A. Roher,et al.  Evidence for Seeding of β-Amyloid by Intracerebral Infusion of Alzheimer Brain Extracts in β-Amyloid Precursor Protein-Transgenic Mice , 2000, The Journal of Neuroscience.

[27]  O Nalcioglu,et al.  Magnetic resonance imaging analysis of age‐related changes in the brains of individuals with Down's syndrome , 1994, Neurology.

[28]  K. Titani,et al.  Down's Syndrome: Up‐Regulation of β‐Amyloid Protein Precursor and τ mRNAs and Their Defective Coordination , 1994 .

[29]  D. Mann,et al.  The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome , 1989, Journal of the Neurological Sciences.

[30]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[32]  A. Gedye,et al.  Dementia Scale for Down Syndrome , 2009 .

[33]  Jerzy Wegiel,et al.  Alzheimer's Disease in Adults with Down Syndrome. , 2008, International review of research in mental retardation.

[34]  D Patterson,et al.  Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. , 2007, Journal of Alzheimer's disease : JAD.

[35]  A. Roher,et al.  Evidence for Seeding of b-Amyloid by Intracerebral Infusion of Alzheimer Brain Extracts in b-Amyloid Precursor Protein-Transgenic Mice , 2000 .

[36]  Scott T. Grafton,et al.  Automated image registration: I. General methods and intrasubject, intramodality validation. , 1998, Journal of computer assisted tomography.